CI3SBIO@EC2612A(17473.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CI3SBIO@EC2612A
17473.HK
News
View More

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

Tip Ranks·
SZ
159102
-0.46%
SH
513700
-1.03%
SZ
159316
-0.74%
Tip Ranks·
SZ
159102
-0.46%
SH
513700
-1.03%
SZ
159316
-0.74%

CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward

The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with four global Phase 3 clinical studies expected to start in 2026. This drug is anticipated to become a cornerstone of the next generation of tumor immunotherapy, driving up 3SBIO's stock price. Based on increased competition, the target price has slightly decreased to 37.43 yuan, maintaining a "Buy" rating

AASTOCKS·
SH
520880
-0.38%
SZ
159316
-0.74%
HK
01530
-1.40%
AASTOCKS·
SH
520880
-0.38%
SZ
159316
-0.74%
HK
01530
-1.40%

The Hang Seng Index fell 0.1% at midday, and the Hang Seng TECH Index dropped 0.4%

36Kr learned that the Hang Seng Index fell 0.1% during the midday break, and the Hang Seng TECH Index dropped 0.4%; the non-ferrous metals, pharmaceutical and biotechnology, and software services sectors led the decline, with Hong Kong Exchanges and Clearing falling over 5%, 3SBIO dropping over 4%, and XUNCE falling over 4%; the energy, durable consumer goods, and building materials sectors strengthened, with WISON ENGRG rising over 7%, POP MART and ARTGO HOLDINGS increasing over 1%; southbound funds net bought HKD 3.955 billion

36Kr·
HK
STECH
-1.00%
HK
01530
-1.40%
HK
03313
-1.35%
36Kr·
HK
STECH
-1.00%
HK
01530
-1.40%
HK
03313
-1.35%

Morning Trend | 3SBIO declines on reduced volume, is the support defense battle about to begin?

As of the close on January 21, 3SBIO (1530.HK) continued to oscillate downward, with trading volume consistently shrinking during the session. The main funds showed a strong wait-and-see sentiment, and the strength to seize rebounds was limited. The daily MACD death cross pattern continued, with green bars expanding, making it difficult to reverse the weak pattern in the short term. Overall, the dominant market sentiment remains defensive, with most short-term funds choosing to enter and exit quickly, showing a clear lack of willingness to sustain long positions. In terms of the industry, the biopharmaceutical sector has recently performed weakly, with the uncertainty of price reductions from centralized procurement and adjustments to the new medical insurance catalog increasing pressure on growth-oriented pharmaceutical companies. 3SBIO has recently lacked new product approvals or significant business developments, and the company's news flow has been bland, leading to a further decrease in market attention. The overall sector is not very hot, and many institutions in the market are taking a wait-and-see approach, with defensive sentiment dominating. From the market perspective, CNY 23.58 has become a key level of divergence between bulls and bears. A short-term breach could indicate a second bottoming signal. A decline on reduced volume typically indicates that active selling is nearing a temporary completion, but if there is no subsequent volume recovery, the downward inertia will still prevail. In terms of intraday performance, there has been some inflow of funds attempting to seize rebounds, but there is a lack of supporting follow-up buying, raising doubts about sustainability during the session. In terms of strategy, it is recommended to keep short-term risk exposure at a low level and closely monitor the trends in medical insurance policies and changes in sector funding. Currently, there are no clear reversal signals from either the technical or fundamental perspectives, and right-side trading users should remain cautious and avoid adding positions against the trend. Only significant positive news, such as new drug approvals or a notable recovery in trading volume, is likely to bring about a phase of rebound opportunities

Technical Forecast·
HK
01530
-1.40%
Technical Forecast·
HK
01530
-1.40%
Posts
View More
© 2026 Longbridge｜Disclaimer